Pharmacoeconomic evidence and considerations for triptan treatment of migraine

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 3, 2002, Pages 237-248

  Caro, J Jaime ^a   Getsios, Denis ^a  

^a CARO RESEARCH INSTITUTE   (United States)

Author keywords

5 HT1B 1D agonists; Costs; Migraine; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; CAFERGOT; DIHYDROERGOTAMINE MESILATE; ELETRIPTAN; FROVATRIPTAN; METOCLOPRAMIDE; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DROWSINESS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; HEALTH CARE COST; HEAT; HUMAN; MEDICAL FEE; MEDICAL RESEARCH; MIGRAINE; OUTCOMES RESEARCH; PARESTHESIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SOCIAL ASPECT; SUPPOSITORY; THORAX PAIN; THROAT DISEASE; VERTIGO;

COST OF ILLNESS; DRUG COSTS; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0036195562     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.3.237     Document Type: Review

References (71)

1. Comorbidity of migraine and major affective disorders
2. Migraine diagnosis and treatment: Results from the American Migraine Study II
3. Increasing incidence of medically recognized migraine headache in a United States population
4. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II
5. The economic burden of migraine to society
6. Burden of migraine in the United States: Disability and economic costs
7. Work-related disability: Results from the American migraine study
8. Impact of migraine in the United States: Data from the National Health Interview Survey
9. Measuring the functional status and well-being of patients with migraine headache
10. Evolution of the measurement of quality of life in migraine
11. Impact of migraine and migraine therapy on productivity and quality of life
12. Acute treatment of migraine attacks
13. Diagnosis and management of migraine
14. Tolerability and appropriate use of sumatriptan: Clinical trials and post marketing experience
15. Safety and rational use of the triptans
16. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs
17. Use of decision analysis in modeling the cost-effectiveness of oral vs. sc. sumatriptan
18. Cost-effectiveness of sumatriptan in a managed care population
19. Sumatriptan: Economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis
20. Cost benefit of sumatriptan to an employer
21. Economic implications of early treatment of migraine with sumatriptan tablets
22. Cost-benefit analysis of sumatriptan tablets versus usual therapy in the treatment of migraine
23. HMO direct costs and health care resource use after implementation of a monthly limit on sumatriptan
24. Subcutaneous sumatriptan compared with usual acute treatments for migraine: Clinical and pharmacoeconomic evaluation
25. Work productivity and resource consumption among migraineurs under current treatment and during treatment with sumatriptan - An economic evaluation of acute treatment in moderate to severe migraineurs
26. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine
27. Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis
28. Impact of sumatriptan on clinic utilization and costs of care in migraineurs
29. Impact of oral sumatriptan 50 mg on work productivity and quality of life in migraineurs
30. The cost-effectiveness of stratified care in the management of migraine
31. Meta-analysis and economic evaluation of sumatriptan for migraine
32. Treatment of migraine in Canada with naratriptan: A cost-effectiveness analysis
33. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine
34. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine
35. Effectiveness of sumatriptan in reducing productivity loss due to migraine: Results of a randomized, double-blind, placebo-controlled clinical trial
36. Sumatriptan treatment for migraine in a health maintenance organization: Economic, humanistic, and clinical outcomes
37. Changes in resource use and outcomes for patients treated with sumatriptan: A managed care perspective
38. Sumatriptan injection reduces productivity loss during a migraine attack. Results of a double-blind, placebo-controlled trial
39. A multinational investigation of the impact of subcutaneous sumatriptan. III. Workplace productivity and non-workplace activity
40. A multinational investigation of the impact of subcutaneous sumatriptan. II. Health-related quality of life
41. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine
42. Improvements in health-related quality of life with sumatriptan treatment for migraine
43. Sumatriptan use in a large group-model health maintenance organization
44. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan
45. Effectiveness of electriptan in reducing time loss caused by migraine attachs
46. Validation of a migraine work and productivity loss questionnaire for use in migraine studies
47. Work and productivity loss in the rizatriptan multiple attack study
48. Evaluation of the costs and outcomes of early migraine treatment with sumatriptan
49. The migraine ACE model: Evaluating the impact of time lost and medical resource use
50. Naratriptan compared with customary therapy: Enhanced quality of life, satisfaction, and productivity
51. Naratriptan compared with nonspecific/nonselective therapies reduces migraine associated lost workplace productivity
52. An economic decision model for chest symptom events associated with triptan use in migraine
53. Cost savings in migraine associated with less chest pain on new triptan therapy
54. Modeling company-wide work loss related to migraine and the productivity benefit of treatment with rizatriptan 10 mg
55. Modeling company-wide work loss related to migraine and avoided loss with rizatriptan 10 mg in Germany
56. The productivity cost benefit of MAXALTΤM vs. usual migraine therapy in Canada
57. Migraine-related employer work loss and potential for avoided loss with rizatriptan 10 mg in Spain
58. Cost per success comparison of rizatriptan and other triptans based on stringent measures of efficacy
59. Stratified care vs. step care strategies for migraine: Results of the Disability in Strategy of Care (DISC) Study
60. Are the triptans for migraine worth the cost?
61. How to calculate indirect costs in economic evaluations
62. The friction cost method for measuring indirect costs of disease
63. Guidelines for pharmacoeconomic studies
64. Different approaches to valuing the lost productivity of patients with migraine
65. Depression scores following migraine treatment in patients attending a specialized center for headache and neurology
66. The value of providing quality-of-life information to managed care decision makers
67. A systematic review of the use of triptans in acute migraine
68. Migraine pharmacotherapy with oral triptans: A rational approach to clinical management
69. 1B/1D agonists
70. 1B/1D agonists in acute migraine treatment: A meta-analysis of 53 trials
71. Evidence-base analysis of a migraine treatment drug comparison trial